CClinicalTrials.gg
Status unknownNCT04069806POC-NaVoPUpdated Sep 16, 2020

Preoperative Oral Carbohydrate for Nausea and Vomiting Prevention During Cesarian Section

An interventional study of preoperative oral carbohydrate, preOp in Postoperative Nausea and Vomiting, sponsored by Pomeranian Medical University Szczecin. Status unknown at 1 site in Poland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Pomeranian Medical University Szczecin · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Post-operative nausea and vomiting (PONV) in women undergoing subarachnoid anesthesia for Caesarean section is an important clinical problem. The aim of this study is to compare the effectiveness of oral carbohydrate loading to standard pre-operative fasting in patients undergoing elective cesarean section on the incidence and severity of PONV and biochemical parameters indicating ketosis.

Read the detailed description

Post-operative nausea and vomiting (PONV) in women undergoing subarachnoid anesthesia for Caesarean section is an important clinical problem. Known mechanisms underlying PONV are based on prolonged fasting, hypotension due to concomitant sympatholysis during anesthesia, bradycardia due to increased vagal tone, visceral stimulation during surgery and intrathecal administered opioids. However, the identification of patients exposed to this problem and appropriate perioperative preparation is of key importance. An analysis of risk factors for postoperative nausea and vomiting in patients undergoing elective cesarean section under spinal anesthesia is of major clinical importance. The aim of this study is a comparison of the effectiveness of oral carbohydrate loading strategy as compared with standard pre-operative fasting in patients undergoing elective cesarean section under spinal anesthesia on the incidence and severity of PONV and biochemical parameters indicating ketosis.

02

Conditions studied

  • Postoperative Nausea and Vomiting

Keywords

  • Nausea
  • Vomiting
  • Oral carbohydrate
  • Fasting
03

In context

Nausea

822 studies on the registry are indexed under Nausea; 104 are open to participants now.

This study's planned enrollment of 140 is above the median of 115 across 703 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

Pomeranian Medical University Szczecin is the lead sponsor of 68 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Age >=18 years.
  2. Scheduled for an elective cesarean section.
  3. Uncomplicated pregnancy.
  4. Planned for spinal anesthesia.
  5. ASA I or ASA II.

Exclusion criteria

Exclusion Criteria:

  1. History of diabetes.
  2. History of gastro-intestinal reflux (GERD).
  3. Unable or unwilling to sign an informed consent.
  4. Contraindications to spinal anesthesia.
  5. Contraindication to Oral carbohydrate formula.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Preoperative oral carbohydrate load

    6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.

    Dietary Supplement: preoperative oral carbohydrate, preOp

  • No intervention
    Standard preoperative fasting

    6 hours for solid food and 2 hours for liquids.

Interventions

  • Dietary supplementpreoperative oral carbohydrate, preOp

    Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.

06

What researchers measure

Primary outcomes

  1. Postoperative nausea and vomiting 6 hours after caesarian section.

    The Postoperative Nausea and Vomiting (PONV) Intensity Scale 6 hours after caesarian section. Scale range: 0-50. The scale measures PONV intensity, where a score ≥50 defined clinically important PONV: PONV Intensity Scale=severity of nausea (1=mild, 2=moderate, 3=severe)×pattern of nausea (1=varying, 2=constant)×duration of nausea (in hours).

    Time frame: 6 hours

  2. Postoperative nausea and vomiting 24 hours after caesarian section.

    The Postoperative Nausea and Vomiting (PONV) Intensity Scale 24 hours after caesarian section. Scale range: 0-50. The scale measures PONV intensity, where a score ≥50 defined clinically important PONV: PONV Intensity Scale=severity of nausea (1=mild, 2=moderate, 3=severe)×pattern of nausea (1=varying, 2=constant)×duration of nausea (in hours).

    Time frame: 24 hours

Secondary outcomes

  1. Time to first peristalsis.

    Moment of first peristalsis after operation (in hours).

    Time frame: 24 hours

  2. Time to first bowel movement.

    Moment of first bowel movement after operation (in hours).

    Time frame: 24 hours

  3. Concentration of serum lactate in serum.

    Lactate level measured in maternal serum.

    Time frame: 0 hours

  4. Concentration of beta-hydroxy-butiric acid in serum.

    Beta-hydroxy-butiric acid level measured in maternal serum.

    Time frame: 0 hours

  5. Insulin resistance factor (HOMA-IR).

    Insulin resistance measured in maternal serum.

    Time frame: 0 hours

  6. Concentration of isoprostane in urine.

    Isoprostane level measured in maternal urine.

    Time frame: 0 hours

07

Study locations

1 of 1 sites recruiting
  • Pomeranian Medical University
    Szczecin, 70-111, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04069806
Lead sponsor
Pomeranian Medical University Szczecin
Responsible party
Katarzyna Kotfis (Primary Investigator, Pomeranian Medical University Szczecin) — Principal investigator
First posted
Aug 28, 2019
Start date
Sep 3, 2019
Primary completion
Mar 31, 2021 (estimated)
Completion
Aug 31, 2021 (estimated)
Last update
Sep 16, 2020

Study contacts

Katarzyna L Kotfis, MD, PhD
Contact
katarzyna.kotfis@pum.edu.pl
0048914661144
Arleta Wojciechowska, RN
Contact
arletawoj@gmail.com
Katarzyna L Kotfis, MD, PhD
principal investigator · Pomeranian Medical University
Sebastian Kwiatkowski, MD, PhD
study chair · Pomeranian Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion